Chronos Archive seal

Review checklist: Gilda Radner (HR-ML026)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the diagnostic pathway from the symptom index, primary cytoreductive surgery for stage IIIC disease, the chemotherapy and its monitoring, the negative germline panel with a somatic BRCA1 variant, and olaparib maintenance.
provenance reviewnot_startedJewish Women's Archive (two pages), Biography.com, TIME (LIFE excerpt), TheWrap, The A.V. Club, Gilda's Club Chicago, Roswell Park, and Wikipedia logged. Her memoir was not read directly; quotations from it are taken from Biography.com and Wikipedia. The family history of ovarian cancer rests on a LIFE excerpt reporting her husband's account.
safe messaging reviewnot_startedThe bulimia, the pregnancy losses, her final admission and her death are recorded as history only, marked sensitive, and kept short; no eating-disorder or mental-health diagnosis is coded; no genetic result is attributed to any real relative.

Judgment calls (dossier editorial resolutions)

  1. Recent-death rule. She died in 1989, so the rule does not apply. Even so, the historical claims are limited to what the fetched sources state. Her memoir, It’s Always Something, was not read directly; the quotation from it is taken from Biography.com, and the dates Wikipedia attributes to it (October 21 and 26, 1986) are recorded with Wikipedia as the source.
  2. The teaching point. The sources agree that about ten months passed between her first symptoms and the diagnosis, with fatigue put down to Epstein-Barr virus, abdominal symptoms to depression or constipation, and pelvic cramps to mittelschmerz, and that the CA-125 test was never done (CLM-0004, CLM-0005). The modern episode reverses this: her four weeks of bloating, early fullness, pelvic pain, and urinary frequency meet the Goff symptom index at the first visit, and examination, CA-125, ultrasound, CT, and biopsy lead to a diagnosis in eight days. Her husband’s view that she “didn’t have to die” is recorded as R, possible (CLM-0012), because whether an earlier diagnosis would have changed the outcome cannot be known.
  3. Family history. The ovarian cancer in her grandmother, an aunt, and a cousin rests on a LIFE book excerpt that reports her husband’s account (CLM-0003, D); the side of the family is not stated, so the family history entries say so. Her father’s brain cancer is from the Jewish Women’s Archive (fourteen when he died) and Wikipedia (a tumor when she was 12; he died two years later). No modern statement, decision, or health fact is attributed to any relative.
  4. Genetic results. The germline panel is negative and the tumor carries a BRCA1 pathogenic variant that is somatic. This was chosen deliberately: a germline variant in her would imply a health fact about her real blood relatives, which the record must not do, while a somatic variant supports the PARP inhibitor teaching. The record therefore documents cascade testing as the step that would follow a germline variant (INT-003, the consultation), and the counselor’s advice that her relatives may still want their own counseling because of the family history. This departs from the assignment’s wording (“cascade testing offered to relatives”) and is a judgment call for the owner. Her real genetic status was never tested; the BRCA genes were identified after her death.
  5. Bulimia and pregnancy losses. Both are documented (CLM-0008, CLM-0007), are marked sensitive, and appear only as past history (PMH-001, PMH-002) and as the synthetic G2 P0 reproductive history. No eating-disorder diagnosis is coded and none is carried into the modern episode.
  6. Index age and dates. The synthetic date of birth is June 28, 1986 (shift 40 years). The index visit on April 6, 2026 maps to April 6, 1986, when she was 39, in the months of fatigue and abdominal symptoms before her real diagnosis. An index age of exactly 40 was not used: at 40 the episode would map to after June 28, 1986, leaving too little time before the November 1, 2026 limit for six cycles of chemotherapy and maintenance, and a later shift would place the presentation after her documented diagnosis. All visits map to April to October 1986, within her lifetime and before her documented diagnosis on October 21, 1986; they are not a claim about where she was. The modern diagnosis in what maps to April 1986 is the intended contrast with the ten months of her real history.
  7. Presenting problem. Persistent bloating and pelvic symptoms with an adnexal mass (R19.00) is the presenting problem at intake, resolved at the consultation on April 14, 2026, when the biopsy result led to the diagnosis of high-grade serous carcinoma of both ovaries (C56.3) and peritoneal metastases (C78.6). The intake documents state only what was known then, including the CA-125 drawn at that visit.
  8. Synthetic clinical picture. All visits, results, imaging, pathology, stage (FIGO IIIC, where the real diagnosis was stage IV), the operation, the regimen and doses (carboplatin AUC 5, 610 mg; paclitaxel 175 mg/m2, 275 mg), the genetic results, her height (160 cm), and her modern spouse are synthetic. The spouse is unnamed and has no role. Qualitative results (pregnancy test, hepatitis B, hepatitis C and HIV tests, rapid influenza and COVID-19 tests, genetic results) are in the note text only.
  9. Sick visit. A cold on day 8 of the second cycle (J06.9), chosen because it is common, interacts with treatment (the expected low white count, with no fever, and a plain fever plan), and insinuates no undocumented real diagnosis.
  10. Preventive visit. A periodic adult preventive visit at 40 (CPT 99396 and 99497 in plain text), four weeks into olaparib: the first monthly blood count on olaparib, a lipid screen (no statin), a screening mammogram ordered at 40, cervical screening not needed after hysterectomy for a non-cervical cancer, a baseline bone density scan after surgical menopause, influenza, COVID-19, PCV20, and the first recombinant zoster dose (immunocompromising therapy), no live vaccines, and advance care planning with an unnamed agent.
  11. Focused visits. The four chronic-care follow-ups (diagnosis and consultation, the first chemotherapy day three weeks after surgery, cycle 4, and the end of chemotherapy) are documented as focused visits on the NCCN ovarian cancer guideline, the ASCO germline and somatic testing, PARP inhibitor, antiemetic, neuropathy, VTE and hepatitis B guidelines, the SGO surveillance recommendations, and USPSTF depression screening. Synthetic findings introduced: surgical menopause (E89.41) at three weeks after surgery and grade 1 paclitaxel neuropathy (G62.0) at cycle 4. One protocol deviation is recorded instead of an invented result: CA-125 was not drawn before cycles 2 and 3, which were given in the infusion center with blood counts only; the value at cycle 4 was already normal, so no harm resulted, and the corrective action is CA-125 at the end of treatment and at each surveillance visit (no earlier values are recorded). The bone density scan planned after treatment is recorded as due at the end of chemotherapy and ordered at the preventive visit.
  12. Consultation. The gynecologic oncology referral and the consultation by Sunita Varghese, MD (a fictional consultant), on the diagnosis day, are S. The consultant answers the five referral questions in line with what the record shows afterwards: clinical stage IIIC; primary cytoreductive surgery a week later with complete gross resection; germline panel and tumor testing (germline negative, somatic BRCA1); hepatitis and HIV screening before chemotherapy (negative); six cycles of carboplatin and paclitaxel, all given on schedule; olaparib maintenance if a BRCA variant was found (started after a complete response); enoxaparin for four weeks; and distress screening with a support group. Her recommendation of CA-125 before each cycle was not fully followed, as the cycle 4 note records.
  13. Real people. Gene Wilder, Joanna Bull, and Joel Siegel appear only in the claims. Her modern spouse and health care agent are unnamed. No other figure with a record in the dataset is named.
  14. Not used. Her memoir itself, Wilder’s memoir and his 1991 People column (known only through TheWrap and TIME), Gilda’s Disease, her medical records, and details of her final illness beyond the facts in CLM-0010 were not fetched and are not used. The name of the Cedars-Sinai program is given as the TIME excerpt gives it; sources differ on its later name. Accounts that symptoms were dismissed as stress or medication side effects, found only on low-quality sites, are not claimed.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-07-14
Progress note 05 (C-CDA)
CA-125At diagnosis; before each cycle when raised at diagnosis; at the end of treatment; then at each surveillance visit21 U/mL today, now normal. A deviation: CA-125 was not drawn before cycles 2 and 3, which were given in the infusion center with blood counts only. No harm resulted: today's value shows a response, and imaging is planned at the end of treatment. Corrective action: CA-125 at the end of treatment and at every surveillance visit; no earlier values are recorded

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-04-14
Progress note 02 (C-CDA)
LaboratoryHepatitis B, hepatitis C and HIV screeningOrderedHepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody, and HIV drawn today
2026-04-14
Progress note 02 (C-CDA)
LaboratoryGermline multigene panelOrderedBRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 and the Lynch syndrome genes; result in about three weeks
2026-09-15
Progress note 06 (C-CDA)
LaboratoryMonthly blood count on olaparibOrderedFirst check in four weeks, at the preventive visit
2026-10-13
Progress note 07 (C-CDA)
PreventionBreast cancer screeningOrderedScreening mammogram every two years from 40; first one ordered today. Her germline panel was negative, so no extra breast imaging is needed for a variant
2026-10-13
Progress note 07 (C-CDA)
PreventionOsteoporosis screeningOrderedPostmenopausal after surgery at 39, so a baseline bone density scan is reasonable

Evidence to check

Retrospective claims (R)

ClaimStatementCertainty
CLM-0012After her death her husband said that no doctor had asked about her family history of ovarian cancer, and wrote that her cancer might have been caught in time if her doctors had given her the CA-125 blood test or asked about that history, and that she 'didn't have to die.'possible

Sensitive claims

ClaimGradeStatement
CLM-0003DHer father died of brain cancer when she was fourteen. Her grandmother, a cousin, and an aunt had all had ovarian cancer.
CLM-0007DBefore her illness she and her husband tried to have a child; she had two miscarriages, one during the filming of Haunted Honeymoon in London, and an unsuccessful round of in vitro fertilization, after which doctors told her she was infertile.
CLM-0008DDuring her Saturday Night Live years her lifelong insecurity about her appearance resurfaced in bouts of bulimia, which she later wrote about.
CLM-0010DIn May 1989 she was admitted to Cedars-Sinai Medical Center in Los Angeles for a CT scan, did not regain consciousness after sedation, and died there three days later, on May 20, 1989, at 42.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-04-06Platelets412 10*3/uL (high)High
2026-04-06CA-1251240 U/mL (high)High
2026-05-12Hemoglobin10.9 g/dL (low)Low
2026-05-12CA-125188 U/mL (high)High
2026-06-09Hemoglobin10.6 g/dL (low)Low
2026-06-09White cell count2.9 10*3/uL (low)Low
2026-06-09Absolute neutrophil count1.3 10*3/uL (low)Low
2026-06-09Platelets142 10*3/uL (low)Low
2026-07-14Hemoglobin10.3 g/dL (low)Low
2026-09-15Hemoglobin11.2 g/dL (low)Low
2026-10-13Hemoglobin10.6 g/dL (low)Low